Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death

Pfizer Press Release (News), NCT05011513 (history)

Pfizer, Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral.., Press Release (News), NCT05011513

Dec 2021 Source PDF

Twitter
Facebook

All Studies Meta

EPIC-SR trial interim results, 428 patients treated with paxlovid (PF-07321332 + ritonavir) and 426 control patients, showing lower hospitalization with treatment. NCT05011513 (history).

Important missing comments or errors? Let us know.

risk of hospitalization, 70.1% lower, RR 0.30, p = 0.05, treatment 3 of 428 (0.7%), control 10 of 426 (2.3%), NNT 61.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Pfizer et al., 14 Dec 2021, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, trial NCT05011513 (history).

All Studies All Outcomes Submit Updates or Corrections

This Paper Paxlovid All

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit